Transcatheter embolization and occlusion refers to passage or insertion of a synthetic embolus through a fine catheter in the blood vessel to obstruct the blood flow in particular area of the body. Transcatheter embolization is a minimally invasive procedure performed as a part of interventional radiology to restrict blood supply to tumors. Synthetic materials known as embolic agents, in some cases, are coated with chemotherapeutic drugs that perform dual action of blocking the blood supply as well as inducing cytotoxicity to attack the tumor in several ways. Moreover, this procedure is also employed to control or prevent abnormal bleeding, eliminate abnormal connections between arteries and veins as well as to treat aneurysms, which refers to formation of a bulge or a sac in weak arterial wall.
Transcatheter embolization is a less invasive and highly efficient way to control bleeding as compared to open invasive surgical procedures. Catheter embolization is considered to be the first line of treatment in gastrointestinal bleeding. This process can be performed alone or combined with other treatments such as surgery or radiation. The process is initiated with the help of x-ray imaging to visualize the blood vessel, after which an interventional radiologist inserts a catheter to the skin into the desired blood vessel and advanced to the treatment site. Among females, this method provides an excellent alternative to hysterectomy to shrink and control heavy menstrual bleeding by interrupting the blood supply caused due to uterine fibroid tumors.
Increasing demand for minimally invasive surgical procedures over conventional open surgeries is expected to propel growth of transcatheter embolization and occlusion devices market. This shift is a result of advantages offered by minimally invasive procedures over open surgeries that includes significantly low blood loss, low recovery time, low surgical time, reduced probability of errors, and others. For instance, according to a retrospective review published by Department of Surgery, John Hopkins Hospital, in 2014, it suggested that the complication and error rates for hysterectomy was 4.69% and 6.64% in catheter embolization and open surgical procedures, respectively.
According to the American Association of Neurological Surgeons 2017, the prevalence of arteriovenous malfunctions (AVM) is estimated at 18 people per 100,000 population in the U.S. Moreover, the AVM is reported to be the second most identifiable cause for subarachnoid hemorrhage. Furthermore, leading players in the market are introducing novel products in the market and this is also expected to aid in growth of the market in the region. For instance, in September 2017, Medtronic Plc expanded its embolization product portfolio with the introduction of Concerto 3D detachable system in the U.S. and Europe that can be used in arterial and venous embolization.
Key players operating in the global transcatheter embolization and occlusion devices market include Boston Scientific Corporation, Terumo Corporation, Cook Medica, DePuy Synthes, Edwards, Eisai, Medtronic Plc, Merit Medical System, Stryker Corporation, St. Jude Medical, Pfizer, Inc., Sirtex Medical, Nordian, and others. Market players are focused on providing technologically advanced products, to sustain their position in the competitive market. For instance, in January 2018, Johnson & Johnson’s Cerenovous division introduced Galaxy G3 Mini embolic coil to remove clots from brain post ischemic strokes.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1683